Welcome to our dedicated page for Longboard Pharmaceuticals news (Ticker: LBPH), a resource for investors and traders seeking the latest updates and insights on Longboard Pharmaceuticals stock.
Longboard Pharmaceuticals, Inc. (LBPH) is a clinical-stage biopharmaceutical company pioneering novel therapies for rare neurological disorders. This dedicated news hub provides investors and industry stakeholders with timely updates on corporate developments, research breakthroughs, and regulatory progress.
Access authoritative information on LBPH's innovative pipeline, including program-specific updates across their portfolio of optimized neurological therapeutics. The resource consolidates official press releases, clinical trial milestones, and strategic partnership announcements in one centralized location.
Key content categories include updates on drug candidate development, regulatory filings, scientific presentations, and corporate governance matters. All materials maintain factual accuracy while avoiding speculative commentary to support informed decision-making.
Bookmark this page for streamlined access to verified LBPH developments. Check regularly for updates on their mission to advance transformative treatments for complex neurological conditions through precision pharmacology.
Longboard Pharmaceuticals (Nasdaq: LBPH), a clinical-stage biopharmaceutical company, announced that CFO Brandi Roberts will present at the 22nd Annual Needham Virtual Healthcare Conference on April 18, 2023, at 4:30 PM ET. The presentation will focus on the company's work in developing transformative medicines for neurological diseases, including candidates LP352 and LP659, which target specific G protein-coupled receptors. A live webcast will be available on Longboard's website, allowing for access to the presentation for at least 30 days afterward.
Longboard Pharmaceuticals aims to advance its pipeline, with LP352 targeting seizures linked to developmental and epileptic encephalopathies and LP659 aimed at multiple neurological conditions. The company emphasizes its commitment to innovation and the potential benefits of its therapies.
Longboard Pharmaceuticals (Nasdaq: LBPH) provided a corporate update and 2022 financial results, highlighting key advancements and plans. Their Phase 1b/2a PACIFIC Study for LP352 is on track for full enrollment in H1 2023, with topline data expected in H2 2023. The company initiated a Phase 1 trial for LP659, anticipating SAD data also in H2 2023. As of December 31, 2022, Longboard reported $67.6 million in cash, with a cash runway extending into mid-2024. The company successfully raised $23 million through a public offering in February 2023, strengthening its financial position and institutional shareholder base.
Longboard Pharmaceuticals, Inc. (NASDAQ: LBPH) announced plans to release its 2022 financial results and provide a corporate update on March 2, 2023. The update will be followed by a conference call at 4:30 PM ET. Investors can participate by pre-registering through a provided link, ensuring timely access. Longboard focuses on developing novel medicines for neurological disorders, including product candidates LP352 and LP659, targeting specific G protein-coupled receptors. The company is positioned to discuss advancements in its clinical pipeline during the call.
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH) has successfully closed its underwritten public offering of 5,750,000 shares of common stock at $4.00 per share, raising approximately $23 million in gross proceeds. The offering included the exercise of an option by underwriters for an additional 750,000 shares. This offering utilized a previously filed shelf registration statement and was managed by Evercore ISI and Cantor Fitzgerald. The funds are aimed at advancing Longboard's clinical-stage pipeline focused on transformative neurological treatments, particularly LP352 and LP659.
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH) announced the pricing of its public offering of 5,000,000 shares at $4.00 per share, aiming to raise approximately $20 million in gross proceeds before expenses. The underwriters were granted a 30-day option for an additional 750,000 shares. Closing of the offering is expected on February 10, 2023. This offering is made under a previously effective shelf registration statement filed with the SEC. Longboard focuses on developing innovative treatments for neurological diseases, including LP352 and LP659, targeting specific G protein-coupled receptors.
